FOR IMMEDIATE RELEASE
Contact: ACIST Medical Systems
ACIST Receives Prestigious Frost & Sullivan Technology Innovation Award
Minneapolis, MN, February 10, 2008 – ACIST Medical Systems, the innovator and market leader in variable-rate contrast injection systems for cardiac and vascular angiography, is pleased to be the recipient of the Frost & Sullivan Technology Innovation Award.
According to Frost and Sullivan, “ACIST Medical Systems’ ability to provide innovative, variable-rate contrast injection solutions for cardiovascular angiography applications has endeared the company to its customers. ACIST offers flexible system configurations to meet the specific needs of the customer, lab workflow and patient. For these reasons, Frost and Sullivan recognize ACIST Medical Systems for its ongoing commitment to excellence in medical technology.”
“This award from Frost & Sullivan is quite an honor. It further validates ACIST’s focus on innovation – especially innovation developed with the purpose of making things better and easier for physicians and their patients around the world,” states Fulvio Renoldi Bracco, CEO of ACIST. “We believe this award demonstrates our commitment to continuous innovation. The ACIST CVi system is a fourth-generation product developed as part of a continuing effort to address customer needs. We look forward to ACIST having even more significant innovations in variable-rate contrast delivery coming to market in the near future.”
ACIST is a world leader in contrast delivery solutions for the imaging field, dedicated to advancing the art of angiography through research and development of new products and technologies – supporting today’s needs and anticipating those of tomorrow. More than four million people around the world have had cardiovascular angiographic procedures using an ACIST system, now at over 1 million annually – and growing. ACIST systems are widely proven in the global health care arena, with clinical usage in over 30 countries and in many world-renowned centers, as well as in community hospitals and university settings.
The Bracco Group is today a worldwide integrated Healthcare Group with annual turnover of about 900 million Euro – around 60% of which is from foreign sales and is one of the world leading companies in the imaging agent business through Bracco Imaging SpA.
Bracco SpA, holding company of the Bracco Group, also markets Ethical and OTC pharmaceutical products and healthcare services in Italy, as well as Advanced Medical Technology systems on a world wide basis through the Bracco AMT companies, ACIST Medical Systems, based in Minneapolis, and Volume Interactions of Singapore.
Bracco is present in approximately 80 countries both directly and through joint-ventures or affiliates, and currently employs more than 2,300 people worldwide over 300 of which are dedicated to R&D, Medical and Regulatory Affairs.
AngioTouch is a registered trademark of ACIST Medical Systems.
About Frost & Sullivan
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company’s Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan’s Growth Partnerships, visit http://www.frost.com.
Contact: Ciara Connolly, Best Practices, Senior Events and Promotions Executive, Frost & Sullivan, P: 44 (0) 207 915 7868, E: email@example.com
This press release may include some products’ commercial brands, which are not to be used unless by media addressed to the medical community.